DrugMapper


Trade Names:	INDAPAMIDE LOZOL
Synonyms:	ARIFON BAJATEN CARDIDE SR DAMIDE ETHIBIDE XL FLUBEST FLUDEX FLUDIN FLUPAMID INDAFLEX INDAMIDE INDAMOL INDAPAMIDA INDAPAMIDE COMPONENT OF BR-1015 INDAXA 2.5 INDIPAM XL IPAMIX KYD-041 LORVAS LOZOL MAPEMID XL NATRILIX NATRILIX SR NATRIX NINDAXA 2.5 NORANAT NSC-757075 OPUMIDE 2.5 RAWEL XL S-1520 SE-1520 TANDIX TENSAID XL TERTENSIF VARBIM XL VEROXIL
Status:	Approved (1983)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	C03BA11
UNII:	F089I0511L


InChI Key	NDDAHWYSQHTHNT-UHFFFAOYSA-N
Smile	CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
InChI	InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)

Action	Mechanism of Action	Reference
INHIBITOR	Thiazide-sensitive sodium-chloride cotransporter inhibitor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	-	0.1607
Enzyme Lyase	-	-	3.77-1420	0.23-0.23	-
Enzyme Oxidoreductase	-	2918	-	-	-
Enzyme Transferase	-	-	-	-	0.586
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-3-1.14
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	80.06
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	144700	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Diabetes Mellitus, Type 2	3	D003924	ClinicalTrials
Essential Hypertension	3	D000075222	ClinicalTrials
Multiple Sclerosis, Chronic Progressive	2	D020528	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	17.0
Infections and infestations Infection	12.0
Metabolism and nutrition disorders Hypochloraemia	9.4
General disorders and administration site conditions Pain	8.0
Cardiac disorders Dizziness	7.0
Musculoskeletal and connective tissue disorders Back pain	5.0
Infections and infestations Rhinitis	5.0
General disorders and administration site conditions Asthenia	4.0
Gastrointestinal disorders Dyspepsia	4.0
Nervous system disorders Headache	3.4
Metabolism and nutrition disorders Hyponatraemia	3.1
Musculoskeletal and connective tissue disorders Hypertonia	3.0
Infections and infestations Influenza	3.0
Cardiac disorders Sinus bradycardia	3.0
Infections and infestations Sinusitis	3.0
Ear and labyrinth disorders Vertigo	2.2
Cardiac disorders Arrhythmia	2.0
Cardiac disorders Chest pain	2.0
Gastrointestinal disorders Constipation	2.0
Respiratory, thoracic and mediastinal disorders Cough	2.0
Gastrointestinal disorders Diarrhoea	2.0
Gastrointestinal disorders Nausea	2.0
General disorders and administration site conditions Oedema	2.0
Gastrointestinal disorders Pharyngitis	2.0
Cardiac disorders Tachycardia	2.0
Cardiac disorders Dizziness	1.9
General disorders and administration site conditions Asthenia	1.7
Musculoskeletal and connective tissue disorders Muscle spasms	1.2
Eye disorders Conjunctivitis	1.0
Psychiatric disorders Nervousness	1.0
Psychiatric disorders Tension	1.0

System Organ Classification (SOC)

	Relative Frequency (%)
Metabolism and nutrition disorders	13.85
Nervous system disorders	13.24
General disorders and administration site conditions	10.55
Cardiac disorders	8.15
Psychiatric disorders	6.62
Vascular disorders	6.62
Gastrointestinal disorders	6.39
Skin and subcutaneous tissue disorders	5.55
Investigations	4.63
Respiratory, thoracic and mediastinal disorders	4.4
Musculoskeletal and connective tissue disorders	3.93
Renal and urinary disorders	3.77
Injury, poisoning and procedural complications	3.29
Immune system disorders	2.26

INDAPAMIDE


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70